Lilly to acquire US radiopharmaceutical company POINT for $1.4bn
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
Sanofi, Janssen partner on potential E. coli pathogenic vaccine
04 Oct 23According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
Regeneron, Intellia expand partnership to develop CRISPR-based therapies
04 Oct 23The expanded collaboration combines Intellia’s genome editing platform with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to develop…
WHO’s advisory group recommends Takeda’s Qdenga vaccine for dengue
04 Oct 23The United Nations’ health agency will consider the SAGE’s recommendation and revise its position paper on dengue vaccines…
Capsida Biotherapeutics, Kate Therapeutics partner to produce KateTx’s next-gen gene therapies
04 Oct 23The collaboration aims to facilitate KateTx's initial internal portfolio of gene therapy programmes focused on muscle and heart…
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate
04 Oct 23The potential development program reflects PharmaEssentia’s efforts to diversify its current expertise and expand its pipeline with a…
Baxter completes $4.5bn sale of BioPharma Solutions business
03 Oct 23Baxter’s BioPharma Solutions business will be renamed Simtra BioPharma Solutions (Simtra), which will continue to same solutions and…
American pharma company Viatris to sell certain businesses for $3.4bn
03 Oct 23The drugmaker has received offer for its OTC business, and has agreed to divest its women's healthcare business,…
Novo Nordisk’s Rivfloza secures FDA nod for adults, children with PH1
03 Oct 23The approval was supported by the positive findings from the Phase 2 PHYOX 2 clinical trial and interim…
UK’s MHRA approves Jemperli with chemotherapy in endometrial cancer treatment
03 Oct 23GSK’s Jemperli plus chemotherapy is now approved for patients with a tumour abnormality called mismatch repair deficient /…